Skip to content

Study · Observational study · 2025

2 results

Healthcare Utilization and Costs of Care in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation After Initiating Oral Therapies: Real-World Analysis in the US Medicare Population.

Shah E, Lee TY, Baldwin Z, Kort J, Ando M, Champaloux SW, Boules M, Sanchez Gonzalez Y

Advances in therapy28 Mar 2025

PMID40153221 (opens in a new tab)PMCIDPMC12006207 (opens in a new tab)DOI10.1007/s12325-025-03163-1 (opens in a new tab)PepBankPUB-40153221
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    In Medicare patients with IBS-C or CIC, plecanatide was associated with higher adjusted total costs than linaclotide at 12 months (P < 0.05).

    In plain wordsMedicare patients receiving plecanatide had higher adjusted total costs than those receiving linaclotide.

    Peptide
    Plecanatide
    Outcome
    IncreaseAll-cause total costs at 12 months
    Study

    n: not reported in source

    Comparator
    Linaclotide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After 12 months follow-up, adjusted all-cause total costs of care were significantly lower among patients who received linaclotide versus lubiprostone or plecanatide, largely driven by lower all-cause medical costs observed in patients who received linaclotide (P < 0.05).
    1 context sentence
    Summary · context
    Retrospective analysis from the Merative™ MarketScan® Medicare Database (January 2017-September 2023),
  2. 02HumanObservational studyOther

    In Medicare patients with IBS-C or CIC, plecanatide was associated with higher all-cause medical costs than linaclotide (P < 0.05).

    In plain wordsMedicare patients receiving plecanatide had higher medical costs than those receiving linaclotide.

    Peptide
    Plecanatide
    Outcome
    IncreaseAll-cause medical costs
    Study

    n: not reported in source

    Comparator
    Linaclotide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    After 12 months follow-up, adjusted all-cause total costs of care were significantly lower among patients who received linaclotide versus lubiprostone or plecanatide, largely driven by lower all-cause medical costs observed in patients who received linaclotide (P < 0.05).
    1 context sentence
    Summary · context
    Retrospective analysis from the Merative™ MarketScan® Medicare Database (January 2017-September 2023),

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.